

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

**QUARTERLY UPDATE ON THE IMPLEMENTATION OF
ACTION PLAN TO RESOLVE THE AUDIT QUALIFICATION**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Touyun Biotech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the annual report of the Company for the year ended 31 December 2025 (the “**2025 Annual Report**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the 2025 Annual Report.

The Board would like to update the shareholders of the Company and potential investors on the measures taken by the Company to resolve disclaimer of opinion as set out below:

1. The Group is currently launching a series of new health products targeting different customer groups for the purpose of continuously expanding the Group’s customers base and stream of revenue. The Board considers that there is growth potential for the Group’s health products market as the population becomes more health conscious.
2. On 30 June 2026, Mr. Wang Liang, a Director, and Ms. Qiao Yanfeng, a shareholder of the Company, provided undertakings to the Company, confirming that they would not demand repayment of the amounts due to them with aggregate amounts of approximately HK\$104.4 million until the Group has sufficient cash reserve to repay the amounts due to them.
3. The Group had successfully obtained to obtain new loans with an aggregate principal amount of approximately HK\$47.7 million from several lenders.

4. The subscription of 123,000,000 new ordinary shares at HK\$0.122 per share was successfully completed on 7 September 2026, generating net proceeds of approximately HK\$14.99 million, which further strengthens the Group's liquidity position for general working capital and debt repayment. Please refer to the Company's announcements dated 25 August 2026, 31 August 2026 and 7 September 2026 for further details.
5. The Group has been negotiating with two of its lenders (the "**Lenders**") for the extension of term of three loans with a principal amount of RMB60 million with maturity date of 7 June 2025, a principal amount of RMB90 million with maturity date of 11 December 2025 and a principal amount of HK\$72.1 million with maturity date of 2 August 2026 respectively (the "**Outstanding Loans**"). The management of the Group is currently in negotiations with the Lenders regarding partial repayment and a further extension of the repayment date for the Outstanding Loans. As at the date of this announcement, the Lenders has not issued any demand for immediate repayment or taken any enforcement action in respect of the Outstanding Loans.
6. The Company has been exploring various options and alternatives to increase the Group's working capital by realisation of the Group's non-core asset items and investments.
7. The Group has been taking active initiatives with a view to enhance the speed of the Group's product distribution and customer reach-out: (i) the Group has been maintaining ongoing discussions with leading supermarket chains/groups, with mutual interest in establishing a formal agreement for the distribution and sale of products of the Group; and (ii) the Group has been keeping an eye on and collaborating with various trending Key Opinion Leaders to promote the Group's products and boost product sales through livestream commerce channels.
8. The Group is actively exploring new business development opportunities with a view to attracting new capital injections and broadening the Group's revenue streams.

The Board will continue to proactively implement relevant measures to resolve the uncertainties related to going concern associated with the disclaimer of opinion and will make further announcements in a timely manner.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 30 September 2026

As at the date of this announcement, the Board comprises the following directors:

Executive Directors

Mr. Wang Liang (*Chairman*)
Ms. Zhou Ruijuan (*Vice chairlady*)
Mr. Du Dong

Non-executive Directors

Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen